Equipoise Therapeutics, based in Cambridge, MA, is a cutting-edge biotechnology company focused on developing programmable therapeutics for various medical conditions. Their innovative RAP Platform and RNA Actuators aim to revolutionize treatment options for patients.
Recently, CAMP4 Therapeutics, a subsidiary of Equipoise Therapeutics, secured Orphan Drug Designation for CMP-CPS-001 to address Urea Cycle Disorders, showcasing the company's commitment to advancing personalized medicine and improving patient outcomes.
Generated from the website